NPS receives 15 proposals for private equity mandates South Korean pension fund to select six firms to award mandates worth $1 billion
Translated by Ryu Ho-joung 공개 2021-04-30 07:59:39
이 기사는 2021년 04월 30일 07:56 thebell 에 표출된 기사입니다.
Tenders launched by the National Pension Service (NPS) to award private equity mandates worth a combined $1 billion have attracted strong attention from investment firms.South Korean state pension fund received 15 proposals after it issued a request for proposals a month ago to invest in traditional private equity funds and co-investment funds, industry sources said.
The pension fund plans to commit a combined 600 billion won ($541.2 million) to four firms for the traditional private equity fund category. The RFP said the applying firms can propose the funding allocation in the range between 80 billion won and 200 billion won.
NPS, which eliminated the fund size categories in its tenders for private equity mandates last year, did the same this year to maximize competition.
It also plans to invest another 600 billion won in two co-investment funds. The pension fund started to award co-investment fund mandates in 2017.
With co-investment funds, NPS can make investment decisions more quickly when investment opportunities arise. For traditional blind-pool funds, general partners need to get approval from limited partners, like NPS, to deploy additional capital to an investment.
NPS will shortlist candidates in the coming weeks, followed by interviews and due diligence. Final selections are expected in June. (Reporting by Hee-yeon Han)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [ICTK road to IPO]경쟁자 없는 '차세대 보안칩', 2000억 후반 밸류 '정조준'
- CG인바이츠, 화일약품 지원 축소 11년 동행 '선긋기'
- [K-바이오 클러스터 기행|대전]대전 바이오 구심점, 20년 역사 바이오헬스케어협회
- 코인원, 이용규 CPO 영입…신규 서비스 출시 속도
- [코스닥 코스메틱 리뉴얼]마스크팩 잘나가던 지피클럽, 색조화장 '코디 인수'
- [K-배터리 밸류업 리포트]'오너 경영체제' 원준, 승계작업 '언제쯤'
- [thebell note]제약바이오는 다이어트 중
- [바이오텍 유증·메자닌 승부수]브릿지바이오, 유무상증자에 '대표 지분 블록딜' 왜?
- [제일약품의 온코닉테라퓨틱스 첫 '신약']성장성·사업성 갖춘 IPO 기대주 '밸류업' 이유 더 있다
- [코스닥 리빌딩 리포트]'조달 지연' 비투엔, 불성실공시법인 지정 가능성은